National Renal Complement Theraputics Centre
Hospitals & Physicians Clinics · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Queen Victoria Road, Newcastle Upon Tyne...Phone Number
+44 1912820385Website
www.atypicalhus.co.ukRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About National Renal Complement Theraputics Centre
The National Renal Complement Therapeutics Centre specializes in the treatment of atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G). They provide access to treatments such as Eculizumab and Ravulizumab for patients suffering from these conditions. Their intended clients include patients diagnosed with aHUS and C3G, as well as healthcare professionals seeking guidance on diagnosis and treatment protocols. The center also engages in clinical research and offers educational resources through roadshows, webinars, and publications.Explore more
National Renal Complement Theraputics Centre Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is National Renal Complement Theraputics Centre your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
National Renal Complement Theraputics Centre, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on National Renal Complement Theraputics Centre recently announced quarterly report
Check if National Renal Complement Theraputics Centre has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when National Renal Complement Theraputics Centre launches new products
Congratulate Masked Content for being promoted to Masked Content at National Renal Complement Theraputics Centre
Click to see if National Renal Complement Theraputics Centre had a recent Job posting/layoffs
Funding: Get notified immidiatlly once National Renal Complement Theraputics Centre has new funding data
Check out if National Renal Complement Theraputics Centre is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined National Renal Complement Theraputics Centre as Masked Content
Find 3 more new buyers
Compare Similar Companies to National Renal Complement Theraputics Centre
Compare insights from companies similar to National Renal Complement Theraputics Centre, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
National Renal Complement Theraputics Centre is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
National Renal Complement Theraputics Centre is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about National Renal Complement Theraputics Centre.
National Renal Complement Theraputics Centre Tech Stack
A closer look at the technologies used by National Renal Complement Theraputics Centre
See more technologies
Top Hospitals & Physicians Clinics Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding National Renal Complement Theraputics Centre
Sign Up For FreeTo access detailed company insights
The National Renal Complement Therapeutics Centre specializes in the treatment of atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G). They provide access to treatments such as Eculizumab and Ravulizumab for patients suffering from these conditions. Their intended clients include patients diagnosed with aHUS and C3G, as well as... Read More
